Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

被引：0
|
作者：
Phillip Chan
Orlanda Goh
Eugène Kroon
Donn Colby
Carlo Sacdalan
Suteeraporn Pinyakorn
Peeriya Prueksakaew
Peter Reiss
Jintanat Ananworanich
Victor Valcour
Serena Spudich
Robert Paul
机构：
[1] SEARCH,United States Military HIV Research Program
[2] The Thai Red Cross AIDS Research Centre,Department of Global Health, Amsterdam University Medical Centers
[3] The Henry M. Jackson Foundation for the Advancement of Military Medicine,Memory and Aging Center, Department of Neurology
[4] Walter Reed Army Institute of Research,Center for Neuroepidemiology and Clinical Neurological Research
[5] University of Amsterdam,Missouri Institute of Mental Health
[6] and Amsterdam Institute for Global Health and Development,undefined
[7] University of California San Francisco,undefined
[8] Yale University,undefined
[9] University of Missouri-St. Louis,undefined
来源：
AIDS Research and Therapy | / 17卷
关键词：
Dolutegravir; Neuropsychiatric adverse events; Depression; RV254; Cognitive performance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort
    Chan, Phillip
    Goh, Orlanda
    Kroon, Eugene
    Colby, Donn
    Sacdalan, Carlo
    Pinyakorn, Suteeraporn
    Prueksakaew, Peeriya
    Reiss, Peter
    Ananworanich, Jintanat
    Valcour, Victor
    Spudich, Serena
    Paul, Robert
    AIDS RESEARCH AND THERAPY, 2020, 17 (01)
  • [2] Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
    Hailu, Workagegnehu
    Tesfaye, Tsebaot
    Tadesse, Abilo
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2021, 14 : 503 - 507
  • [3] Hospitalization outcomes in people living with HIV on Dolutegravir-based regimen in Mwanza, Tanzania: a comparative cohort
    Kisigo, Godfrey A.
    Barongo, Eric
    Issarow, Benson
    Cichowitz, Cody
    Wajanga, Bahati
    Kalluvya, Samuel
    Peck, Robert N.
    AIDS RESEARCH AND THERAPY, 2025, 22 (01):
  • [4] Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study
    Dorward, Jienchi
    Sookrajh, Yukteshwar
    Khubone, Thokozani
    van der Molen, Johan
    Govender, Riona
    Phakathi, Sifiso
    Lewis, Lara
    Bottomley, Christian
    Maraj, Munthra
    Lessells, Richard J.
    Naidoo, Kogieleum
    Butler, Christopher C.
    Van Heerden, Rose
    Garrett, Nigel
    LANCET HIV, 2023, 10 (05): : E284 - E294
  • [5] HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis
    Loosli, Tom
    Hossmann, Stefanie
    Ingle, Suzanne M.
    Okhai, Hajra
    Kusejko, Katharina
    Mouton, Johannes
    Bellecave, Pantxika
    van Sighem, Ard
    Stecher, Melanie
    Monforte, Antonella d'Arminio
    Gill, M. John
    Sabin, Caroline A.
    Maartens, Gary
    Guenthard, Huldrych F.
    Sterne, Jonathan A. C.
    Lessells, Richard
    Egger, Matthias
    Kouyos, Roger D.
    LANCET HIV, 2023, 10 (11): : E733 - E741
  • [6] Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients
    Nasreddine, Rakan
    Florence, Eric
    Vandercam, Bernard
    Moutschen, Michel
    Goffard, Jean-Christophe
    de Munter, Paul
    Delforge, Marc
    Marinus, Wouter
    De Wit, Stephane
    AIDS, 2020, 34 (08) : 1151 - 1159
  • [7] Effectiveness of Dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients
    Nasreddine, R.
    Florence, E.
    Vandercam, B.
    Moutschen, M.
    Goffard, J-C
    De Munter, P.
    Delforge, M.
    De Wit, S.
    HIV MEDICINE, 2019, 20 : 68 - 69
  • [8] Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV cohort study
    Mugglin, C.
    Calmy, A.
    Guenthard, H.
    Tarr, P.
    Atkinson, A.
    Scherrer, A.
    Cavassini, M.
    Marzolini, C.
    Schmid, P.
    Bernasconi, E.
    Braun, D.
    Wandeler, G.
    Rauch, A.
    HIV MEDICINE, 2019, 20 : 9 - 9
  • [9] Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV
    Sribenjalux, Wantin
    Nuntawit, Tharatorn
    Meesing, Atibordee
    Chetchotisakd, Ploenchan
    INTERNATIONAL JOURNAL OF STD & AIDS, 2022, : 98 - 107
  • [10] Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho
    Brown, Jennifer A.
    Nsakala, Bienvenu L.
    Mokhele, Kuena
    Rakuoane, Itumeleng
    Muhairwe, Josephine
    Glass, Tracy R.
    Amstutz, Alain
    Tschumi, Nadine
    Belus, Jennifer M.
    Klimkait, Thomas
    Labhardt, Niklaus D.
    HIV MEDICINE, 2023, 24 (02) : 153 - 162
12345